

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

PASSING AWAY OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

The board (the “**Board**”) of directors (the “**Directors**”) of Genscript Biotech Corporation (the “**Company**”) hereby announces with deepest sorrow that Dr. Alphonse Galdes (“**Dr. Galdes**”), an independent non-executive Director and a member of the audit committee (the “**Audit Committee**”) of the Company, was confirmed passing away on 13 September 2026 (Hong Kong Time).

Dr. Galdes had served the Board as an independent non-executive Director since September 2024. The Board records its profound appreciation for Dr. Galdes’s invaluable guidance and distinguished contributions to the Company throughout his tenure. On behalf of the Company, the Board also conveys its sincere condolences to the family of Dr. Galdes.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board further announces the following changes in the composition of the committees of the Company: (i) Dr. Victor Shi, an independent non-executive Director, has been appointed as a new member of the Audit Committee with effect from 16 September 2026; and (ii) Dr. Victor Shi has ceased to be a member of the nomination committee (the “**Nomination Committee**”) and the strategy committee (the “**Strategy Committee**”) of the Company with effect from the same date.

Following the passing away of Dr. Galdes and the above changes in the composition of the committees: (1) the Board comprises nine Directors, including four executive Directors and five independent non-executive Directors, (ii) the Audit Committee comprises three members, namely Mr. Andy Cheung (*chairman*), Mr. Ethan Pan and Dr. Victor Shi; (iii) the Nomination Committee comprises five members, namely Mr. Robin Meng (*chairman*), Mr. Andy Cheung, Mr. Ethan Pan, Mr. Ross Grossman and Ms. Sally Wang; and (iv) the Strategy Committee comprises three members, namely Dr. Frank Zhang (*chairman*), Mr. Ethan Pan and Dr. John Quelch. The Company meets the minimum number of independent non-executive directors as required under Rule 3.10(i) of the Rules Governing the Listing of Securities on The Stock

Exchange of Hong Kong Limited (the “**Listing Rules**”) and the minimum number of members in the Audit Committee as required under Rule 3.21 of the Listing Rules.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 16 September 2026

*As at the date of this announcement, the executive Directors are Mr. Jiange Meng (“**Mr. Robin Meng**”), Dr. Fangliang Zhang (“**Dr. Frank Zhang**”), Dr. Li Zhu and Ms. Ye Wang (“**Ms. Sally Wang**”); and the independent non-executive Directors are Mr. Yiu Leung Andy Cheung (“**Mr. Andy Cheung**”), Mr. Jiuan Pan (“**Mr. Ethan Pan**”), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi (“**Dr. Victor Shi**”).*